Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Aducanumab

Catalog #:   DHC12504 Specific References (100) DATASHEET
Host species: Human
Isotype: IgG1-kappa
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHC12504

Description

Aducanumab (brand name: Aduhelm) is an amyloid beta-directed monoclonal antibody that targets amyloid beta in the brains of people with Alzheimer’s to reduce its buildup. Aducanumab is a monoclonal antibody (a protein that helps your immune system target other proteins), and it is designed to help your body remove something called amyloid beta from the brain. Amyloid beta is an important protein involved in the progression of Alzheimer’s disease. Aducanumab is given intravenously (infused through a vein) monthly. Aducanumab does not cure Alzheimer’s disease, but one (of two) large clinical studies suggests that aducanumab may slow the progression of the earliest symptoms of Alzheimer’s disease.

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59, AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein, Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF, Gamma-CTF(57), AICD-50

Concentration

2.3 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P05067

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

BART, BIIB-037, CAS: 1384260-65-4

Clone ID

Aducanumab

Data Image
  • SDS-PAGE
    SDS PAGE for Aducanumab
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

A resurrection of aducanumab for Alzheimer's disease, PMID: 31978357

Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019, PMID: 33135381

Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval, PMID: 32787971

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease, PMID: 29067304

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease, PMID: 27582220

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β, PMID: 29686315

Aducanumab and the FDA - where are we now?, PMID: 33442064

Aducanumab reduces Aβ plaques in Alzheimer's disease, PMID: 27739124

Alzheimer disease and aducanumab: adjusting our approach, PMID: 31138932

Questions EMERGE as Biogen claims aducanumab turnaround, PMID: 31784690

Drug treatments in Alzheimer's disease, PMID: 27251914

Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab, PMID: 29777003

Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease, PMID: 29181491

Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice, PMID: 27810931

Post-hoc analysis could give new life to the Alzheimer's drug aducanumab, PMID: 33139929

Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019", PMID: 33135288

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease, PMID: 28640269

Alzheimer's disease: Recent treatment strategies, PMID: 32941929

Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab, PMID: 33072846

Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease, PMID: 33252074

Antibodies to watch in 2020, PMID: 31847708

The amyloid hypothesis of Alzheimer's disease at 25 years, PMID: 27025652

Aducanumab, PMID: 34424635

Aducanumab: First Approval, PMID: 34324167

Aducanumab, PMID: 34251780

Aducanumab-avwa, PMID: 34268554

From monomer to fibril: Abeta-amyloid binding to Aducanumab antibody studied by molecular dynamics simulation, PMID: 32666627

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease, PMID: 30610216

Aducanumab: What about the Patient?, PMID: 34322904

Alzheimer's disease: targeting the glutamatergic system, PMID: 32048098

Drug candidates in clinical trials for Alzheimer's disease, PMID: 28720101

Aducanumab for Alzheimer's disease?, PMID: 34226181

Why aducanumab is important, PMID: 34413516

Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs, PMID: 32772738

Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies, PMID: 32989305

Aducanumab and the certainty of evidence, PMID: 34405228

Pathways Connecting Late-Life Depression and Dementia, PMID: 32231570

Efficacy and safety of anti-amyloid- β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis, PMID: 29296624

Passive antiamyloid immunotherapy for Alzheimer's disease, PMID: 32040044

The next steps in curing Alzheimer's disease, PMID: 31699316

Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials, PMID: 33321511

AMDA Position Statement on Aducanumab, PMID: 34456010

The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis, PMID: 31706733

Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life, PMID: 33199898

Aducanumab: Appropriate use recommendations, PMID: 34314093

[Aducanumab and Alzheimer's disease: a critical reflection], PMID: 34263875

Aducanumab: look before leaping, PMID: 34413517

Aducanumab, amyloid, and culture wars, PMID: 34413026

The Problem of Aducanumab for the Treatment of Alzheimer Disease, PMID: 34138642

Aducanumab: The first targeted Alzheimer's therapy, PMID: 34234067

Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system., PMID:40520157

Antiamyloid treatment for dementia: concerns outweigh hopes., PMID:40511512

Disease severity across psychiatric disorders is linked to pro-inflammatory cytokines., PMID:40505822

Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer disease brain., PMID:40475543

Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species., PMID:40448101

Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference., PMID:40437880

[Prospects for treating Alzheimer's disease]., PMID:40420451

Anti-amyloid immunotherapies for Alzheimer's disease: Administration, side effects, and overall framework., PMID:40413817

Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease., PMID:40413110

Aducanumab delivery via focused ultrasound-induced transient blood-brain barrier opening in vivo., PMID:40404732

TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease., PMID:40390253

Comparative efficacy, tolerability, and acceptability of aducanumab, lecanemab, and donanemab with repetitive transcranial magnetic stimulation on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis., PMID:40386876

Juxtacortical Lesion Precedes Lobar Microbleed During Anti-amyloid β Immunotherapy., PMID:40368787

Cortical microstructural abnormalities in dementia with Lewy bodies and their associations with Alzheimer's disease copathologies., PMID:40355490

The Efficacy of Anti-amyloid Monoclonal Antibodies in Early Alzheimer's Dementia: A Systematic Review., PMID:40346804

Use of Model-Based Meta-Analysis to Inform the Design of Early Clinical Trials of Anti-Amyloid Beta Therapies in Alzheimer's Disease., PMID:40344388

The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis., PMID:40316479

Clinically meaningful benefit and real-world evidence in Alzheimer's disease research and care., PMID:40291121

A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases., PMID:40290431

Cost-effectiveness analysis of aducanumab versus placebo for patients with mild cognitive impairment and mild Alzheimer's disease., PMID:40250880

The science does not yet support regulatory approval of amyloid-targeting therapies for Alzheimer's disease based solely on biomarker evidence., PMID:40243238

Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease., PMID:40237235

The Importance of Vaccines in Preventing Impending Alzheimer's Epidemic., PMID:40231511

Global experience in brain amyloid imaging., PMID:40222870

Longitudinal Evolution of Posterior Cortical Atrophy: Diagnostic Delays, Overlapping Phenotypes, and Clinical Outcomes., PMID:40198862

Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application., PMID:40194268

A review of public comments submitted to the Centers for Medicare and Medicaid Services in response to the 2022 National Coverage Decision on treatment for Alzheimer's disease., PMID:40190585

A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system., PMID:40170724

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer's disease to individuals with mild cognitive impairment or early Alzheimer's disease in the general population., PMID:40122980

Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions., PMID:40118715

Developing Treatment Models for the Delivery of the Antiamyloid Therapy, Lecanemab: Considerations for Implementation of Lecanemab in Healthcare Systems., PMID:40058984

Demographic and clinical characteristics of initial patients receiving amyloid-targeting treatments in the United States after regulatory approval., PMID:40042495

Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease., PMID:40011174

Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics., PMID:40011173

Targeting Amyloid Pathology in Early Alzheimer's: The Promise of Donanemab-Azbt., PMID:39998021

Plasma Alzheimer's disease biomarker relationships with incident abnormal amyloid PET., PMID:39989078

Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer's Treatment., PMID:39980294

Chimeric Antigen Receptors Discriminate Between Tau and Distinct Amyloid-Beta Species., PMID:39974919

[Diagnosis and Treatment of Alzheimer's Disease: Current Update]., PMID:39958494

Correction to: Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab., PMID:39945923

Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting., PMID:39935618

Drug-induced dementia: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database., PMID:39882323

Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives., PMID:39865265

Aducanumab in Alzheimer's Disease: A Comparative Study of Its Effects on Dementia and Mild Cognitive Impairment., PMID:39830554

Multi-Targeting Phytochemicals for Alzheimer's Disease., PMID:39815655

Therapeutic Options in Alzheimer's Disease: From Classic Acetylcholinesterase Inhibitors to Multi-Target Drugs with Pleiotropic Activity., PMID:39768263

Safety Concerns in Neurological Clinical Trials: A Challenge That the FDA Must Resolve., PMID:39767824

Mining and analysis of adverse events associated with aducanumab: a real-world study using FDA Adverse Event Reporting System database., PMID:39726994

Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials., PMID:39711072

Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting., PMID:39708177

Datasheet

Document Download

Research Grade Aducanumab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Aducanumab [DHC12504]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only